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Abstract
Objective: This post-hoc analysis compared the lipid-altering efficacy of Ezetimibe/Simvastatin 10/20 mg (EZ/Simva)
versus Rosuvastatin 10 mg (Rosuva) in patients stratified by statin potency/dose prior to randomization.
Methods: Patients with elevated low-density lipoprotein cholesterol (LDL-C) despite prior statin treatment (n =
618) were randomized 1:1 to EZ/Simva 10/20 mg or Rosuva 10 mg for 6 weeks. Percent change from baseline in
lipids and attainment of lipid targets were assessed within each subgroup (low potency n = 369, high potency n =
249). Consistency of the treatment effect across subgroups was evaluated by testing for treatment-by-subgroup
interaction. No multiplicity adjustments were made.
Results: Significant treatment-by-subgroup interaction occurred for LDL-C (p = 0.013), total cholesterol (p = 0.025),
non-HDL-C (p = 0.032), and apolipoprotein B (p = 0.016) with greater between-treatment differences in favor of
EZ/Simva observed in patients from the high potency stratum vs low potency stratum. Individual and triple target
attainment was higher for Eze/Simva compared with Rosuva in both strata.
Conclusions: Compared with Rosuva, switching to EZ/Simva provided greater reductions in LDL-C, total
cholesterol, non-HDL-C and apolipoprotein B and higher target attainment in patients on prior statin treatment,
regardless of potency, although patients treated with higher potency statins prior to randomization experienced
greater between treatment differences in favor of EZ/Simva.
Trial Registration: Registered at ClinicalTrials.gov: NCT00479713.
Background
Low-density lipoprotein cholesterol (LDL-C) is the pri-
mary target of therapy in patients with hypercholestero-
lemia[1,2]. If therapeutic lifestyle changes do not lower
LDL-C to recommended levels, interventions such as
HMG-CoA reductase inhibitors (statins) are indicated
for further LDL-C reductions. Rosuvastatin has demon-
strated more effective LDL-C reductions across its dose
range than other statins across their dose ranges and
greater lipid-lowering effects compared with the other
marketed statins[3-5]. However, despite the substantial
lipid-lowering associated with the use of statins, LDL-C
reductions beyond that achieved by currently used statin
therapies–even those considered to be of highest
potency–are recommended for a considerable number
of patients[6-9]. Many patients at high cardiovascular
risk and/or with severely elevated LDL-C do not achieve
the rigorous treatment targets recommended by Eur-
opean, Canadian and US guidelines using established
statin treatment regimens[1,2,10,11].
Clinical trial results have demonstrated that combin-
ing ezetimibe with a statin more effectively lowers LDL-
C than therapy with either of the individual components
alone[9,12]. In a study of ezetimibe combined with
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at each dose comparison and across doses, ezetimibe/
simvastatin reduced LDL-C levels significantly more
than rosuvastatin[13]. That trial utilized a placebo run-
in, which may not reflect usual clinical practice in which
high cardiovascular risk patients are usually already
being treated with a statin and require dose adjustments
or treatment changes to achieve desired lipid levels. In
the trial presented here patients were treated prior to
randomization with statins of varying potency but had
not achieved LDL-C <100 mg/dL[14]. The results of the
primary analysis of this trial demonstrated significantly
greater reductions in LDL-C and other lipid levels and
significantly greater achievement of prespecified LDL-C
treatment targets with ezetimibe/simvastatin 10/20 mg
(EZ/Simva) versus rosuvastatin 10 mg (Rosuva) in the
overall population following 6 weeks of treatment[14].
The objective of this post hoc analysis was to compare
the lipid-altering efficacy of two treatment regimens
recommended for clinical use. Analyses were done in
patients grouped by statin potency/dose prior to
randomization.
Methods
The methods for this study were previously published
[ 1 4 ] .B r i e f l y ,t h i sw a sam u l ticenter, randomized, dou-
ble-blind, parallel-group study conducted at 85 sites in
10 countries in Europe between March 2007 and March
2008. The study protocol was approved by the appropri-
ate ethics committees and institutional review boards at
each site, and all patients provided written informed
consent before any study procedures were administered.
Patients
Men and women 18 to 80 years of age with documented
hypercholesterolemia [LDL-C ≥100 and ≤190 mg/dL at
screening and ≥100 and ≤160 mg/dL at randomization]
and high cardiovascular risk who were taking a stable
daily dose of atorvastatin 10 or 20 mg; fluvastatin 80
mg; pravastatin 40 mg; rosuvastatin 5 mg; or simva 20
or 40 mg for at least 6 weeks prior to the study rando-
mization were enrolled in the study. Patients were con-
sidered high cardiovascularr i s ki ft h e yh a dah i s t o r yo f
CHD (i.e. stable and unstable angina, revascularization
procedure, myocardial infarction, documented silent
myocardial ischemia), or with established vascular ather-
osclerotic disease (i.e. peripheral vascular disease,
ischemic stroke); type 2 diabetes without a history of
vascular disease and with high cardiovascular risk (i.e.
renal impairment [proteinuria >300 mg/24 h or creati-
nine clearance (standardized for body surface area)
<1.002 ml/s] and/or at least two CHD risk factors per
Framingham risk calculation); or CHD risk >20% over
10 years as determined by the Framingham risk
calculation. All patients must have had fasting triglycer-
ide levels <350 mg/dL, alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) levels ≤1.5 × the
upper limit of normal (ULN), and creatine kinase (CK)
levels ≤ 3 × ULN at baseline.
Patients were excluded if they had conditions or medi-
cations other than reported statin medications that
could have affected lipid levels; active liver disease; con-
gestive heart failure; poorly controlled diabetes [hemo-
globin A1c (HbA1c) ≥8.5%]; uncontrolled hypertension
(systolic >160 mmHg or diastolic >100 mmHg); or
impaired renal function (creatinine ≥176.8 mmol/L).
Patients taking prescription and/or over-the counter-
drugs with the potential for significant lipid effects
(other than study drug or above listed statins), or with
potential drug interactions with the statins were also
excluded from the study.
Treatments
At screening, patients were enrolled in the open-label
run-in phase during which they continued to receive
their current dose/brand of statin medication for 6
weeks. At randomization, eligible patients received
either EZ/Simva 10/20 mg/day or rosuvastatin 10 mg/
day for 6 weeks. Patients were counseled regarding diet
and exercise at each clinic visit.
Efficacy measures
In patients grouped by potency of statin at baseline (low
potency stratum included simvastatin 20 mg, pravastatin
40 mg, fluvastatin 80 mg, atorvastatin 10 mg and high
potency stratum included simvastatin 40 mg, atorvasta-
tin 20 mg, rosuvastatin 5 mg), the percent change from
baseline in LDL-C, total cholesterol, HDL-C, non-HDL-
C, triglycerides, hs-CRP, LDL-C/HDL-C ratio, total
cholesterol/HDL-C ratio and Apo B were assessed. In
addition, the percentage of patients achieving LDL-C
<100 mg/dL, <77 mg/dL, or <70 mg/dL; non-HDL-C
<130 mg/dL or <100 mg/dL; Apo B <90 or <80 mg/dL;
and achievement of the combination of LDL-C <100
mg/dL, non-HDL-C <130 mg/dL and Apo B <90 mg/dL
was assessed.
Statistical Methods
The analyses were based on the Full-Analysis-Set (FAS)
population which included all patients who received
randomized treatment and had a baseline and at least
one measurement performed after treatment start. The
efficacy analyses for LDL-C, total cholesterol, HDL-C,
non-HDL-C, LDL-C/HDL-C ratio, total cholesterol/
HDL-C ratio and Apo B were analyzed using a para-
metric ANOVA model. The consistency of the treat-
ment effect across the two strata subgroups (low/high
potency) was assessed through the significance of the
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model with terms for treatment, baseline efficacy vari-
able (categorized based on quartiles), study center, stra-
tum subgroup and the treatment-by-stratum subgroup
interaction. The least-square (LS) means and 95% confi-
dence intervals (CIs) within each subgroup level were
used to quantify the difference between treatment
groups from the above ANOVA model (except for the
last two terms involving subgroup). Consistency of the
treatment effects on triglycerides and hs-CRP were
assessed through the significance of the treatment-by-
subgroup interaction term in the ANOVA model on
ranks of these efficacy variables with terms for treat-
ment, baseline triglycerides (or hs-CRP) categorized
based on quartiles, study center, stratum potency status
and the treatment-by-stratum subgroup interaction. The
difference between treatment groups was quantified
using the difference in medians and 95% CIs using
Hodges-Lehmann estimates within each subgroup.
The percentages of patients that achieved specified
targets at endpoint were analyzed via a logistic regres-
sion model. The consistency of the treatment effect
across the two strata subgroups was assessed through
the significance of the treatment-by-subgroup interac-
tion term in the logistic regression model with terms for
treatment, baseline lipid variable as continuous variable,
stratum status, and treatment-by-stratum subgroup
interaction. Odds ratio estimates and 95% CIs were
derived from the logistic regression model with similar
terms except for the last two involving subgroups. Due
to the exploratory nature of this analysis, no multiplicity
adjustments nor power computation were employed.
Results
Baseline
The flow of patients through the study was previously
published[14]. In the EZ/Simva group (N = 314) there
were 189 patients taking low-potency statins and 125
patients taking high-potency statins at baseline. In the
rosuvastatin group (N = 304), there were 180 patients
taking low-potency statins and 124 patients taking high-
potency statins at baseline. Within each potency strata
group, baseline demographic and clinical characteristics
were generally well-balanced, although there were more
patients with diabetes in the low-potency statin group
compared with the high-potency statin group (Table 1
and Table 2).
Efficacy endpoints
Both treatment regimens resulted in improvements in
LDL-C, non-HDL-C, total cholesterol, triglyceride, Apo
B, LDL-C/HDL-C ratio and total cholesterol/HDL-C
ratio levels after 6 weeks of treatment, although the per-
cent change from baseline was greater in patients
treated with EZ/Simva 10/20 mg for all endpoints com-
pared with patients treated with rosuvastatin 10 mg in
both potency strata groups (Figure 1 and Figure 2). Sig-
nificant treatment-by-stratum interactions were
observed for LDL-C (p = 0.013), total cholesterol (p =
0.025), non-HDL-C (p = 0.032), and Apo B (p = 0.016),
with greater between treatment differences in favor of
EZ/Simva observed in patients from the high-potency
stratum compared with the low-potency stratum (Figure
1 and Figure 2). Treatment effects were consistent
across the two subgroups (low-potency/high-potency)
with the overall population in HDL-C, LDL-C/HDL-C,
total cholesterol/HDL-C ratio, hs-CRP and triglyceride
levels.
Higher percentages of patients achieved the specified
treatment targets in the EZ/Simva group compared with
patients treated with rosuvastatin in both potency
groups (Figures 3 and Figure 4). The magnitude of
between-group differences was generally greater in the
high-potency statin group compared with the low-
potency statin group. In the low-potency group, the pre-
dictive odds of attaining all individual specified lipid
levels and the triple combination were greater in
patients treated with EZ/Simva compared with rosuvas-
tatin (see table under Figure 3). In the high-potency
group, the predictive odds of attaining all individual spe-
cified lipid levels and thet r i p l ec o m b i n a t i o nw e r e
greater in patients treated with EZ/Simva compared
with rosuvastatin (see table under Figure 4). In the high-
potency group, the predictive odds of attaining the lipid
levels were higher compared with those in the low-
potency groups, although the treatment effects on
attainment of specified levels for LDL-C, non-HDL-C,
Apo B and the triple combination target were generally
consistent across the two potency groups.
Discussion
This post hoc analysis demonstrated that in patients
with hypercholesterolemia at high risk for CHD who
had not attained specified LDL-C treatment levels,
switching to EZ/Simva 10/20 from high- or low-potency
statins resulted in greater further reductions in most
lipid levels compared with switching to rosuvastatin 10
mg for 6 weeks. In addition, switching to EZ/Simva 10/
20 from high- or low-potency statins results in superior
achievement of specified lipid targets vs rosuvastatin 10
mg treatment.
The mean duration of hypercholesterolemia in patients
enrolled in this study was 8 years, which suggests that
patients were either candidates for or had received long-
term treatment prior to study start but had not yet
achieved suggested therapeutic targets. One would expect
that with high-potency statin treatment, over time patients
would achieve lower lipid levels than with low-potency
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who had been treated with statins for a minimum of 6
weeks prior to study start, and quite possibly for much
longer than 6 weeks, baseline lipid levels were similar
between the two statin potency groups. Therefore, even
with what may be considered more intensive statin mono-
therapy, a considerable number of patients did not achieve
therapeutic targets on statin monotherapy.
Of note the magnitude of response to the combination
treatment appeared to be greater in terms of percent
change from baseline in patients in the high-potency
g r o u pv sp a t i e n t si nt h el o w - p o t e n c yg r o u p .M o r e o v e r ,
the odds of attaining most specified lipid levels (espe-
cially the LDL-C targets) in the high-potency group was
double or triple the odds of attaining specified lipid
levels in the low-potency group. These results suggest
that some subjects in the high-potency group may be
poor responders to statins. One reason for poor
response to statin therapy and inadequate goal achieve-
ment may be inter-individual variability in LDL-C low-
ering, which has been reported with high-potency
statins[15]. Similar inter-individual variability has also
been shown with ezetimibe[16], but to date, even if no
studies have been published demonstrating this same
variability with the combination treatment, the compli-
mentary mechanisms targeting the synthesis and absorp-
tion of cholesterol may explain the better efficacy in
patients who are poor responders to statins.
Table 1 Baseline demographics and risk factors
Low Potency* High Potency
†
E/S 10/20
(n = 189)
R1 0
(n = 180)
Total
(N = 369)
E/S 10/20
(n = 125)
R1 0
(n = 124)
Total
(N = 249)
Male, n (%) 74 (39.2) 77 (42.8) 151 (40.9) 55 (44.0) 42 (33.9) 97 (39.0)
Female, n (%) 115 (60.8) 103 (57.2) 218 (59.1) 70 (56.0) 82 (66.1) 152 (61.0)
Mean Age, y (SD) 63.4 (9.3) 63.5 (10.6) 63.5 (10.0) 62.9 (10.5) 62.4 (9.1) 62.7 (9.8)
Race n (%)
White 189 (100) 180 (100) 369 (100) 125 (100) 122 (98.4) 247 (99.2)
Other 2 (1.6) 2 (0.8)
BMI <30 kg/m
2‡ (%) 128 (67.7) 134 (74.4) 262 (71.0) 88 (70.4) 87 (70.2) 175 (70.3)
BMI ≥30 kg/m
2‡ (%) 61 (32.3) 46 (25.6) 107 (29.0) 36 (28.8) 37 (29.8) 73 (29.3)
Risk factors [n (%)]
CHD 90 (47.6) 84 (46.7) 174 (47.2) 62 (49.6) 60 (48.4) 122 (49.0)
Diabetes 60 (31.7) 52 (28.9) 112 (30.4) 35 (28.0) 26 (21.0) 61 (24.5)
Ex-smoker 37 (19.6) 44 (24.4) 81 (22.0) 40 (32.0) 26 (21.0) 66 (26.5)
Non smoker 94 (49.7) 87 (48.3) 181 (49.1) 50 (40.0) 51 (41.1) 101 (40.6)
Smoker 58 (30.7) 49 (27.2) 107 (29.0) 35 (28.0) 47 (37.9) 82 (32.9)
E = ezetimibe; BMI = body mass index; CHD = coronary heart disease; n = number; R = rosuvastatin; S = simvastatin; SD = standard deviation; y = year
*Low potency stratum included: simvastatin 20 mg, pravastatin 40 mg, fluvastatin 80 mg, atorvastatin 10 mg
†High potency stratum included: simvastatin 40 mg, atorvastatin 20 mg, rosuvastatin 5 mg
‡Missing data for 1 patient in the high potency EZ/Simva group
Table 2 Baseline clinical characteristics
Low Potency High Potency
Mean (SD) E/S 10/20
(n = 189)
R1 0
(n = 180)
Total
(N = 369)
E/S 10/20
(n = 125)
R1 0
(n = 124)
Total
(N = 249)
LDL-C (mg/dL) 125.2 (16.3) 124.2 (16.7) 124.7 (16.5) 121.2 (15.7) 126.7 (16.6) 123.9 (16.3)
HDL-C (mg/dL) 55.9 (15.1) 55.0 (13.7) 55.4 (14.4) 54.7 (12.9) 55.0 (13.6) 54.9 (13.2)
non-HDL-C (mg/dL) 153.0 (21.4) 150.5 (21.1) 151.8 (21.2) 150.4 (21.0) 156.0 (21.6) 153.1 (21.5)
TC (mg/dL) 208.9 (22.7) 205.5 (22.6) 207.2 (22.7) 205.1 (21.2) 210.9 (23.4) 208.0 (22.4)
TG (mg/dL)* 125.0 (72.6) 116.0 (68.8) 121.0 (70.7) 134.5 (75.3) 135.0 (77.7) 135.0 (75.3)
Apo B (mg/L) 119.4 (19.5) 115.4 (21.7) 117.4 (20.7) 119.3 (20.1) 122.4 (18.5) 120.8 (19.4)
hs-CRP (mg/L)* 1.7 (2.7) 1.4 (2.2) 1.6 (2.5) 1.4 (2.1) 1.6 (2.9) 1.6 (2.4)
LDL-C/HDL-C 2.4 (0.7) 2.4 (0.7) 2.4 (0.7) 2.3 (0.6) 2.4 (0.7) 2.4 (0.6)
TC/HDL-C 3.9 (0.9) 3.9 (0.9) 3.9 (0.9) 3.9 (0.9) 4.0 (0.9) 4.0 (0.9)
Apo B = apolipoprotein B; E = ezetimibe; hs-CRP = high-sensitivity C-reactive protein; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density
lipoprotein cholesterol; R = rosuvastatin; S = simvastatin; TG = triglycerides; TC = total cholesterol
*presented as median values with standard deviation (SD) calculated by (Q3-Q1)/1.075
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research has begun to illuminate potential reasons why
the response to statins and other drugs varies widely
among individuals. Non-modifiable factors that may
impact statin response include sex and age but these
associations have not been fully elucidated. Variability
associated with age may be attributed to poor compli-
ance[17] or altered kidney function, which may be
remedied through close monitoring and dose adjust-
ment[18]; and hormone fluctu a t i o n sm a yp l a yar o l ei n
the variability observed in the elderly and between sexes
[19]. Some differences in statin response may be attribu-
ted to genetic variations in pharmacokinetic- and phar-
macodynamic-related genes. Genetic variations in LDL
receptor expression were shown to be associated with
diminished statin response (i.e., diminished effects of
statins on in vivo lipid reductions and on in vitro LDL
receptor induction); and similarly, attenuated statin-
mediated changes were observed in subjects with genetic
mutations in HMG CoA reductase[20].
Without solid scientific evidence and pharmacogenetic
tests to inform clinical decisions, individual patient
response to statin monotherapy is likely the only way to
assess the need to modify dosages or therapies to attain
lipid goals. Although statins are typically considered the
first line of therapy for lipid-lowering, this can prove to
be a time-consuming and expensive endeavor for
patients who respond suboptimally to statins. These
patients are candidates for combination therapy with
complimentary mechanisms of action, such as ezetimibe
added to statin; and clinical trial results support an
approach to lipid-lowering that targets the synthesis and
the absorption of cholesterol in patients with suboptimal
response to statin monotherapy [14,21,22]. Using a Mar-
kov model, the use of ezetimibe in combination with
simvastatin was projected to be a cost-effective
Figure 1 Percent change in lipid and hs-CRP levels after 6 weeks of treatment in patients treated with low-potency statins* at
baseline. *Low potency stratum included: simvastatin 20 mg, pravastatin 40 mg, fluvastatin 80 mg, atorvastatin 10 mg.
†Presented as median
values. Apo B = apolipoprotein B; E = ezetimibe; hs-CRP = high-sensitivity C-reactive protein; LDL-C = low-density lipoprotein cholesterol; HDL-C
= high-density lipoprotein cholesterol; R = rosuvastatin; S = simvastatin; TG = triglycerides; Total C = total cholesterol.
Figure 2 Percent change in lipid and hs-CRP levels after 6 weeks of treatment in patients treated with high-potency statins* at
baseline. *High potency stratum included: simvastatin 40 mg, atorvastatin 20 mg, rosuvastatin 5 mg
†Presented as median values Apo B =
apolipoprotein B; E = ezetimibe; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; hs-CRP = high
sensitivity C-reactive protein; R = rosuvastatin; S = simvastatin; TG = triglycerides; Total C = total cholesterol.
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† at baseline). *Triple target = LDL-C
<100 mg/dL and non-HDL-C <130 mg/dL and Apo B <90 mg/dL
†Low potency stratum included: simvastatin 20 mg, pravastatin 40 mg,
fluvastatin 80 mg, atorvastatin 10 mg
‡Ratio of the predictive odds of attaining target on EZ+Simva versus Rosuvastatin based on the logistic
model (fitted within each subgroup) with terms for treatment and baseline values of the variable being modeled. Apo B = apolipoprotein B; E =
ezetimibe; LDL-C = low-density lipoprotein cholesterol; non-HDL-C = non-high-density lipoprotein cholesterol; R = rosuvastatin; S = simvastatin.
Figure 4 Percent of patients achieving lipid targets at 6 weeks (treated with high-potency statins
† at baseline). *Triple target = LDL-C
<100 mg/dL and non-HDL-C <130 mg/dL and Apo B <90 mg/dL
†High potency stratum included: simvastatin 40 mg, atorvastatin 20 mg,
rosuvastatin 5 mg
‡Ratio of the predictive odds of attaining target on EZ+Simva versus Rosuvastatin based on the logistic model (fitted within
each subgroup) with terms for treatment and baseline values of the variable being modeled. Apo B = apolipoprotein B; E = ezetimibe; LDL-C =
low-density lipoprotein cholesterol; non-HDL-C = non-high-density lipoprotein cholesterol; R = rosuvastatin; S = simvastatin.
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tin,[23] and the results of the present analyses further
support the use of EZ/Simva 10/20 mg vs rosuvastatin
10 mg, a high potency statin, for improving hypercholes-
terolemia in patients who had not achieved LDL-C tar-
gets on previous statin monotherapy, regardless of
potency. Studies to demonstrate the efficacy of ezeti-
mibe/statins vs statins on clinical outcomes are under
way[24].
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